MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--VIVUS, Inc. (NASDAQ: VVUS), a biopharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announced that data from the phase 3 EQUATE trial (OB-301) of Qnexa™ in obese patients will be presented at the 17th annual European Congress on Obesity (ECO) in Amsterdam, The Netherlands. Qnexa, an investigational new drug for the treatment of obesity, simultaneously addresses both appetite and satiety – the two main mechanisms that impact eating behavior.
